202 related articles for article (PubMed ID: 6600195)
1. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
Kurata S; Tsuchiya T; Norimura T; Yamashita U
J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
[TBL] [Abstract][Full Text] [Related]
2. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
5. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
[TBL] [Abstract][Full Text] [Related]
6. Effector mechanism of tumor immunity in murine plasmacytoma.
Chen YH; Anderson AB
Cancer Res; 1988 Mar; 48(6):1398-403. PubMed ID: 3257896
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
8. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
9. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
10. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
[TBL] [Abstract][Full Text] [Related]
11. Virus-dependent cytostatic activity to mammary tumor cells of lymphocytes from normal mice.
Gillette RW; Lowery LT
Cancer Res; 1976 Nov; 36(11 Pt 1):4008-14. PubMed ID: 184922
[TBL] [Abstract][Full Text] [Related]
12. Effector mechanism in antitumor activity of monoclonal antibodies produced against an ascitic mouse mammary tumor.
Seto M; Takahashi T; Nakamura S; Saito M; Hara T; Nishizuka Y
Cancer Res; 1986 Apr; 46(4 Pt 2):2056-61. PubMed ID: 3004718
[TBL] [Abstract][Full Text] [Related]
13. Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.
Mitani M; Matsumoto T; Mori K; Miake S; Himeno K; Nomoto K
J Clin Lab Immunol; 1985 Oct; 18(2):97-101. PubMed ID: 3935795
[TBL] [Abstract][Full Text] [Related]
14. Dysfunction of Ia-positive antigen-presenting cells in tumor-bearing mice.
Yamashita U
Jpn J Cancer Res; 1987 Mar; 78(3):261-9. PubMed ID: 3106282
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
Liew FY; Howard JG; Hale C
J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
[TBL] [Abstract][Full Text] [Related]
16. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
[TBL] [Abstract][Full Text] [Related]
17. Accessory cell activity of murine tumor-associated macrophages.
Dougherty GJ; McBride WH
J Natl Cancer Inst; 1986 Mar; 76(3):541-8. PubMed ID: 3512894
[TBL] [Abstract][Full Text] [Related]
18. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
[TBL] [Abstract][Full Text] [Related]
19. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
Fuyama S; Yamamoto H; Arai S
Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
[TBL] [Abstract][Full Text] [Related]
20. In vitro induction of polyclonal killer T cells with 2-mercaptoethanol and the essential role of macrophages in this process.
Igarashi T; Okada M; Kishimoto T; Yamamura Y
J Immunol; 1977 May; 118(5):1697-703. PubMed ID: 67145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
